Irbesartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-1097

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Irbesartan And Hydrochlorothiazide (NDC 71335-1097). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1a (Image 1)

A line graph depicting the percentage of systolic blood pressure (SBP) less than 140 mmHg versus baseline SBP (mmHg) across different studies involving Irbesartan and Hydrochlorothiazide (HCTZ) combinations and individual components. The graph compares data from Study V and Study VI for Irbesartan and HCTZ combined, Irbesartan alone, and HCTZ alone, illustrating trends in blood pressure reduction efficacy.*

FDA Label Image

Figure 1b (Image 2)

A line graph comparing the percentage of patients with systolic blood pressure (SBP) under 130 mmHg across different baseline SBP values (140 to 220 mmHg). The graph includes data lines for Irbesartan and Hydrochlorothiazide Study V, Irbesartan Study V, Hydrochlorothiazide Study V, Irbesartan and Hydrochlorothiazide Study VI, and Irbesartan Study VI.*

FDA Label Image

Image02a (Image 3)

A line graph showing the percentage of diastolic blood pressure (DBP) less than 90 mmHg versus baseline DBP in mmHg. The graph compares different studies and treatments: Irbesartan and Hydrochlorothiazide combined, Irbesartan alone, and Hydrochlorothiazide alone, across multiple studies (V and VI). Each treatment is represented by distinct lines and markers in the graph.*

FDA Label Image

Image02b (Image 4)

A line graph depicting the percentage of diastolic blood pressure (DBP) less than 80 mmHg over baseline DBP values (mmHg). The graph compares results from studies labeled Irbesartan and HCTZ Study V, Irbesartan Study V, HCTZ Study V, Irbesartan and HCTZ Study VI, and Irbesartan Study VI, showing differences in treatment effects.*

FDA Label Image

Irbesartan Chemical Structure (Image 5)

Chemical structure of Irbesartan, showing its molecular framework with multiple rings and substituents including a cyclopentanone group and a tetrazole ring.*

FDA Label Image

Hctz Chemical Structure (Image 6)

Chemical structure of Irbesartan and Hydrochlorothiazide, the active ingredients in the film-coated tablet combination for oral use by Bryant Ranch Prepack.*

FDA Label Image

Figure03 (Image 7)

A scatter plot with a fitted curve showing the relationship between Irbesartan dose (mg/day) on the x-axis and blood pressure reduction (mmHg) on the y-axis. Data points illustrate variability in response at different doses, with reduction values ranging roughly from 0 to 12 mmHg.*

FDA Label Image

Figure04 (Image 8)

A scatter plot with a curve showing the relationship between Irbesartan dose (mg/day) on the x-axis and mmHg (blood pressure measure) on the y-axis. The plot indicates changes in mmHg values as the Irbesartan dose increases up to about 900 mg/day.*

FDA Label Image

Label Image (Lbl713351097)

Label for Irbesartan and Hydrochlorothiazide Tablets, USP, 150 mg/12.5 mg, film-coated tablets. The label includes the NDC 71335-1097-1, the manufacturer Bryant Ranch Prepack, and states a package quantity of 30 tablets. Storage instructions and drug content details are also visible.*

FDA Label Image

Lbl7133510972

Label for Irbesartan Hctz 150/12.5 mg tablet, film coated, oral dosage form. The label states it is packaged by Bryant Ranch Prepack in Burbank, CA. It includes storage instructions at room temperature (20°-25°C), a barcode, lot number 1523487, and an NDC of 71335-1097-1. The label also references comparison to Avalide 150/12.5 mg tablet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.